Follow-up duration
Approximately 1 year (This is an estimate and may vary in accordance with the specified time windows for each attendance.) Planned Trial Period 2 years (1 year following enrolment of last volunteer)
Primary Objective
To assess the safety of a new influenza vaccine, MVA-NP+M1, when administered as a single dose to healthy volunteers. Secondary Objective To assess the cellular immune response generated by a new influenza vaccine, MVA-NP+M1, when administered as a single dose to healthy volunteers. 
Investigational Products

MVA-NP+M1
FBC
Full blood count
GCP
Good Clinical Practice
GMO
Genetically modified organism
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Gene Therapy Advisory Committee
HA Haemaglutinin
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Hepatitis B Surface Antigen
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Human Chorionic Gonadotrophin
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Hepatitis C virus
HIV
Human immunodeficiency virus
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Human leukocyte antigen
IDT
Impfstoffwerk Dessau-Tornau
IEC
Independent Ethics Committee
LSM
Local safety monitor
M1
Matrix protein 1 
MHRA
Medicines and Healthcare products Regulatory Agency
MVA
Modified Vaccinia Virus Ankara
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4.
BACKGROUND AND RATIONALE
The need for a new vaccine against influenza
Seasonal influenza has a huge annual impact worldwide, accounting for tens of millions of illnesses, hundreds of thousands of excess hospitalizations, and tens of thousands of excess deaths in the US alone [1] . Recent infections of avian influenza (H5N1) in humans could lead to a new pandemic if the virus acquires the ability to transmit between humans, with potentially devastating effects across the world [2] . Current widely-used vaccines for seasonal influenza A act by stimulating production of antibodies to HA and NA.
As these proteins are highly polymorphic, there is very little or no cross-subtype (or heterosubtypic) protection and limited cross-strain protection even within subtypes. Each year a selection of highly prevalent strains are chosen as the basis for vaccine production, for a vaccine that will be used for one season only. This need for constant redesign and remanufacture increases the cost of the vaccines, places limitations on supply [3] , and most importantly means that vaccines for newly arising strains can only be produced once the HA and NA sequences of viruses posing the greatest threat to human health have been identified.
Two recent trials of new investigational H5N1 vaccines [4, 5] suggested that a 12 fold greater amount of antigen would be need per vaccine course than with other flu vaccines.
This has discouraged further development of vaccines by companies who are concerned that if a pandemic does not occur they will be left with unsold supplies, although other trials have found that the use of adjuvants can reduce the amount of antigen needed [6] . Moreover, the current high rate of diversification of H5N1 strains suggests that vaccines made now may differ so much in their H5 sequence from any pandemic strain that emerges that these vaccines would have little or no efficacy. Avian influenza in humans is currently treated with the anti-viral drug oseltamivir, and this drug is now being stockpiled for use in future pandemics. However, oseltamivir resistant H5N1 virus has now been isolated following human infection [7] , so the use of this drug alone may not be sufficient to treat infected individuals and limit the spread of the virus should it become transmissible from human to human.
The development of a novel vaccination strategy against influenza
Antibodies against the external proteins of influenza can prevent the virus from infecting cells and either prevent infection or limit the spread of infection. However the surface proteins are highly variable and there is little antibody cross-reactivity between variants. Once a cell has been infected with the virus, it is then vulnerable to T cell attack resulting in the destruction of infected cells so that no more virus can be produced and the infection is controlled. There is evidence from clinical trials of influenza challenge [8] , and animal models [9] that T cell responses can protect in the absence of antibodies. Additionally, since T cells can recognise the highly conserved internal proteins of influenza, cross-subtype protection can be achieved [10] .
Seasonal influenza infection results in a T cell response to the virus which can protect against subsequent infection. Recent studies in Oxford have shown that 90% of the adult population have detectable T cell responses to one or more influenza antigens (Tao Dong, unpublished). However over the course of a few years these responses decline below protective levels. The new vaccine being tested in this study is designed to boost these T cell responses back to protective levels. Even responses that may be too low to be reliably quantified by currently available assays may still be boosted to high levels by a single dose of recombinant MVA as shown by the tuberculosis vaccine study [11] . Since the internal proteins vary little between influenza subtypes, this could result in a 'universal' vaccine against influenza A. If the need to continually reformulate the vaccine in response to mutations in the viral coat proteins can be removed, the universal vaccine could be produced in large amounts and used more widely than the existing seasonal 'flu vaccines, thus protecting the population against currently circulating viruses and new virus types that are at present only found in avian species. Responses to M1 and 2 were tested together, but in the small number of volunteers were these were separated the response was predominantly to M1 rather than M2. identical between H3N2 and H1N1 strains, and 91% identical between H3N2 and H5N1 strains. M1 is 95% identical between H3N2 and H1N1 strains, and 93% identical between H3N2 and H5N1 strains. This low level of variation appears to allow strong T cell crossreactivity. For comparison, the sequence of TRAP antigen used in our malaria vaccine differs by 8% from the sequence in the challenge strain, and excellent immunological crossreactivity and cross-strain protection was observed [12] . In addition, each of the antigens (NP and M1) is recognised in a T cell assay by more than 70% of the local population (Tao Dong, unpublished, see Figure 1 ). antigen by prior exposure to environmental mycobacteria, and that the immunisation with MVA 85A then boosted pre-existing memory responses rather than priming a T cell response de novo. Volunteers given BCG followed by MVA85A four weeks later produced even higher T cell responses to Antigen 85A, and these were maintained for longer; at least two years.
HA
The same was true of volunteers who had been vaccinated with BCG in the past (median time 18 years prior to MVA vaccination, range 0.5 -38 years).
In clinical studies with new malaria vaccines, recombinant MVA was found to boost T cell responses in malaria-naïve subjects who had been primed with either a DNA vaccine or recombinant fowlpox expressing the same antigen [12, 13] .
Recombinant modified vaccinia virus Ankara as a vaccine vector
The successful worldwide eradication of smallpox via vaccination with live vaccinia virus highlighted vaccinia as a candidate virus for recombinant use. MVA is a highly attenuated strain of vaccinia virus that is unable to replicate efficiently in human cell lines and most mammalian cells [14] . MVA underwent multiple, fully characterised deletions during more than 570 passages through chicken embryo fibroblast cells [15] This fades over the next few weeks and is not usually apparent at 2 months after vaccination. Febrile symptoms in the first 2 days after vaccination are reported by some volunteers, particularly at higher doses, but are not always accompanied by a measured rise in temperature. A minority of volunteers experienced a mild headache during this period.
MVA85A has also been given to small numbers of adults with latent TB infection or HIV infection. No additional adverse events were reported.
MVA expressing malaria antigens has been used in many studies in the UK and Africa, in adults and children, and these are summarised in Table 2 . Adverse events were the same as those reported for MVA-85A; mild or moderate, self-limited local and/or systemic events.
In addition MVA expressing HIV antigens has been administered to 16 chronically HIVinfected adults. Vaccinations were well tolerated and there were no serious adverse events.
No breakthrough viraemia occurred after immunisations or throughout follow-up [25] . The same vaccine has been administered to 192 healthy adults [26] and was found to be safe and well-tolerated. MVA-NP+M1. Safety data will be collected. The secondary aim of this study will be to assess the cellular immune responses generated by each dose.
Potential Risks
The general risks to participants in this Phase I study are associated with phlebotomy and with vaccination. The volume of blood drawn over the 1-year study period (up to 650mL) should not compromise these otherwise healthy volunteers. Potential risks include local and systemic reactions, which are described below. As vaccine-related side effects are believed to be related more to the vector used than the specific insert, it is expected that MVA-NP+M1
will have a similar side effect profile to recombinant MVA viruses encoding other antigens. To date the safety data of all 43 volunteers to receive MVA-NP+M1 has been excellent, with no serious adverse events recorded.
Local reactions
Mild tenderness, bruising, light-headedness or, rarely, syncope, may result from venepuncture. Vaccination usually precipitates a local inflammatory reaction. This may include redness, swelling, scaling, tenderness, or itching. In previous studies using recombinant MVA vaccines, these local reactions have spontaneously resolved within weeks.
Systemic Reactions
Systemic reactions that could potentially occur following immunisation with a recombinant MVA vaccine include a flu-like illness with low-grade fever, chills and malaise. In general, it appears that the frequency of systemic side effects in response to recombinant MVA vaccines is affected by a preceding poxvirus vaccination, with the proportion of volunteers experiencing any systemic side effects after the first vaccination being 69%, decreasing to 37% after the second and 22% after a third immunisation. As with any other vaccine, the Guillain-Barré syndrome, (GBS) or immune mediated reactions that can lead to organ damage may occur. However, this has never been seen with a recombinant MVA vaccine.
As with any vaccine, serious allergic reactions may occur.
Known Potential Benefits
Volunteers will not benefit directly from participation in this study. However, it is hoped that the information gained from this study will contribute to the development of a safe and effective influenza vaccine regime. The only benefits for participants would be information about their general health status.
OBJECTIVES
Primary Objectives
To assess the safety of a new influenza vaccine, MVA-NP+M1, when administered to healthy volunteers.
Secondary Objectives
To assess the cellular immune response generated by MVA-NP+M1, when administered to healthy volunteers.
6.
INVESTIGATIONAL PRODUCTS
The vaccine to be used in this study is MVA-NP+M1. 
MVA-NP+M1 formulation and dose
Each vial of MVA-NP+M1 contains 600 microlitres volume at a concentration of 1.3 x 10 8 pfu/ml in 10mM Tris buffer. The doses of MVA-NP+M1 to be used in this study will be 5 x10 7 pfu, 1.5 x10 8 pfu and 2.5 x 10 8 pfu.
Vaccine administration
On vaccination day, vaccine will be allowed to thaw to room temperature and administered within 1 hour. The vaccine will be administered either intradermally or intramuscularly into the deltoid region of the arm. The investigators will wear gloves and eye protection. Volunteers will stay in the unit for 30 minutes (±10 minutes) after vaccination. During administration of the vaccine, medicines and resuscitation equipment will be immediately available for the management of anaphylaxis.
As volunteers may already have T cell responses to NP and M1, these will be measured by elispot assay on blood taken at both the screening visit and on the day of vaccination, in order to determine the existing responses, and subsequently the increase in T cell responses induced by vaccination.
Minimising environmental contamination with Genetically Modified
Organisms (GMO)
In order to minimise dissemination of the recombinant vectored vaccine virus into the environment, the inoculation site will be covered with a dressing after immunisation. This should absorb any virus that may leak out through the needle track. The dressing will be removed from the injection site after 30 minutes (± 10 minutes) and will be disposed as GMO and current standard UK practice.
Vaccine labels
The vaccines will be labelled as detailed below: 
Box label FOR CLINICAL TRIAL USE ONLY
7.
RECRUITMENT AND WITHDRAWAL OF TRIAL VOLUNTEERS
Volunteers
All subjects in this study will be recruited through a combination of poster campaigns, website advertising, email, mail-shots, radio announcements, newspaper adverts and flyers distributed from stalls or stands at exhibitions or fairs.
Informed Consent
All volunteers will sign and date the informed consent form before any study specific procedures are performed. The information sheet will be made available to the volunteer at least 24 hours prior to the screening visit. At the screening visit, the volunteer will be fully informed of all aspects of the trial, the potential risks and their obligations. The following general principles will be emphasised:
• Participation in the study is entirely voluntary
• Refusal to participate involves no penalty or loss of medical benefits
• The volunteer may withdraw from the study at any time
• The volunteer is free to ask questions at any time to allow him or her to understand the purpose of the study and the procedures involved
• The study involves research of an investigational vaccine
• There is no direct benefit for participating
• The volunteer's GP will be contacted to corroborate their medical history
The aims of the study and all tests to be carried out will be explained. The volunteer will be given the opportunity to ask about details of the trial, and will then have time to consider whether or not to participate. If they do decide to participate, they will sign and date two copies of the consent form, one for them to take away and keep, and one to be stored in the Case Report Form (CRF). These forms will also be signed and dated by the one of the Investigators.
Inclusion and Exclusion Criteria
This study will be conducted in healthy adults, who meet the following inclusion and exclusion criteria.
Inclusion Criteria
The volunteer must satisfy all the following criteria to be eligible for the study:
• Healthy adult 18 or over, no upper age limit
• Resident in or near Oxford for the duration of the vaccination study
• Able and willing (in the Investigators' opinions) to comply with all study requirements
• Willing to allow the investigators to discuss the volunteer's medical history with their
General Practitioner
• For females, a negative pregnancy test on the day of vaccination and agreement to practice effective contraception for the duration of the study, or greater than 12 months since last menstruation, in the absence of hormonal contraception (i.e. post menopausal).
• Agreement to refrain from blood donation during the course of the study
• Written informed consent
Exclusion Criteria
The volunteer may not enter the study if any of the following apply:
• Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
• Prior receipt of a recombinant MVA vaccine
• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
• Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
• Any history of anaphylaxis in reaction to vaccination
• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
• History of serious psychiatric condition
• Any chronic illness requiring ongoing or awaiting hospital specialist supervision, other than minor surgical procedures and follow up of surgery over 6 months prior to screening.
• Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)
• Seropositive for hepatitis B surface antigen (HBsAg)
• Seropositive for hepatitis C virus (antibodies to HCV)
• For females, pregnancy, lactation or willingness/intention to become pregnant during the study
• Any other significant disease, disorder or finding, which, in the opinion of the Investigators, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study.
• Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis, as determined by the investigators.
Withdrawal of Volunteers
Volunteers may withdraw or be withdrawn for any of the reasons given below. The reason for withdrawal will be recorded in the CRF. If withdrawal is due to an adverse event, appropriate follow-up visits or medical care will be arranged until the adverse event has resolved or stabilised. Any volunteer who is withdrawn from the study may be replaced, if that is possible within the specified time frame. The Local Safety Monitor (LSM) may recommend withdrawal of volunteers (see Section 11.6).
Discontinuation Criteria
In • Administrative decision by the Investigators
• Pregnancy
• Ineligibility (either arising during the study or retrospective, having been overlooked at screening)
• Significant protocol deviation
• Volunteer non-compliance with treatment regime or study requirements
• An adverse event which requires discontinuation of the vaccination regimen or results in inability to continue to comply with study procedures (see below)
Contraindications to vaccination
The following adverse events constitute contraindications to administration of vaccine at that point in time. If any one of these adverse events occurs at the time scheduled for vaccination, the volunteer may be vaccinated at a later date, or withdrawn at the discretion of the Investigators:
• Acute disease at the time of vaccination, defined as the presence of a moderate or severe illness with or without fever
• Temperature of ≥37.5°C at the time of vaccination (All vaccines can be administered to persons with a minor illness, such as diarrhoea or mild upper respiratory infection, with or without low-grade febrile illness, i.e., temperature of <37.5°C)
Compliance with Dosing Regime
All doses in this vaccine study will be administered by the one of the Investigators and recorded in the CRF. The study medication will be at no time in the possession of the volunteer and compliance will not, therefore, be an issue.
Pregnancy
Should a volunteer become pregnant during the trial, she will be followed according to the protocol, but in addition will be followed until pregnancy outcome.
TRIAL DESIGN
Primary and Secondary Endpoints
The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. The specific endpoints for immunogenicity will be markers of cellmediated immunity.
Study Groups
This is an open Phase 1 study of a recombinant MVA expressing NP and M1 in three groups of healthy volunteers (12 in the ID arm, 16 in the IM arm and 30 in the age stratified IM arm).
The first IM arm will be split into 2 groups of 8. The first 8 will receive the low dose vaccine, followed by the second 8 who will receive the high dose vaccine. The 3rd group will be split into 3 groups of 10 volunteers in the age ranges 50-59, 60-69 and 70 and above.
Duration of Study
Each volunteer will attend for one vaccination, on the day of enrolment. The follow up visits are as described in section 9.2, with a final visit approximately one year after enrolment.
Definition of the Start and End of the Trial
The start of the trial is defined as the date of the first vaccination of the first volunteer. The end of the trial is the date of the last visit of the last volunteer.
9.
TREATMENT OF TRIAL VOLUNTEERS
Study procedures
Procedures will be performed on the visit time points indicated in the schedule of procedures.
Additional procedures or laboratory tests may be performed, at the discretion of the Investigators e.g. urine microscopy in the event of positive urinalysis.
Observations
Observations which will be documented are pulse, blood pressure and temperature.
Blood Tests
Blood will be drawn for the following laboratory tests:
1.
At the Oxford Radcliffe Hospitals NHS Trust Laboratories, using NHS standard procedures:
• Haematology; Full Blood Count
• Biochemistry; Sodium, Potassium, Urea, Creatinine, Albumin, Liver Function Tests,
Glucose
• Diagnostic serology; HBsAg, HCV antibodies, HIV antibodies (Counselling will be given prior to testing blood for these blood-borne viruses)
• Immunology; Human Leucocyte Antigen (HLA) typing
At University of Oxford research laboratories:
Exploratory Immunology; Ex vivo Elispot assays for interferon gamma will be performed. Other exploratory immunological assays, including Elispot assays for interleukin-2 and tumour necrosis factor alpha, may be performed at the discretion of the Investigators. These may include gene expression studies. Some of this blood will be required for immediate use and the remainder stored for up to 15 years as a future research source, with the consent of the volunteers.
Urinalysis
Urine will be tested for protein and glucose at screening. For pre-menopausal female volunteers only, urine will be tested for beta-Human Chorionic Gonadotrophin (HCG) at screening and immediately prior to vaccination.
Vaccinations
Before each vaccination, the on-going eligibility of the volunteer will be reviewed. The vaccine will be administered as described above in section 6.4. The injection site will be covered with a sterile dressing and the volunteer will stay in the CCVTM for 30 minutes (± 10 minutes) after vaccination, in case of immediate adverse events. Observations will be taken 30 minutes (± 10 minutes) after vaccination and the sterile dressing removed and injection site inspected. An oral thermometer, tape measure and diary card will be given to each volunteer, with instructions on use.
Study visits
The study visits and procedures will be undertaken by one of the Investigators. The procedures to be included in each visit are documented in the schedules of attendances (tables 3 and 4). Each visit is assigned a time point and a window period, within which the visit will be conducted. These can be found in the schedules of attendances.
Screening Visit
All potential volunteers will have a screening visit, which may take place up to 90 days prior to vaccination. Informed consent will be taken before screening, as described in section 7.2.
If consent is obtained, the screening procedures indicated in the schedule of procedures will be undertaken.
Visits for volunteers Day 0 Enrolment and first vaccination
The eligibility of the volunteer will be reviewed at the end of the screening visit and again when all results from the screening visit have been considered. If eligible, a day 0 visit will be scheduled for the volunteer to receive the vaccine. Volunteers will not be considered enrolled in the study until they have received their vaccine. The vaccine will be administered in the non-dominant arm or both arms for high dose IM vaccination. 2 and weeks 1, 3, 8, 12 , 24, 52)
Subsequent visits (day
On subsequent visits, the volunteers will be assessed for local and systemic adverse events, using a diary card, interim history, physical examination and blood tests at the time points indicated in the schedule of attendances. Blood will also be taken for exploratory immunology analysis. 
ASSESSMENT OF SCIENTIFIC OBJECTIVES
Primary Outcome Measures
To assess the safety of a candidate influenza vaccine, MVA-NP+M1 in healthy adult volunteers. The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.
Secondary Outcome Measures
To assess the immunogenicity of a candidate influenza vaccine, MVA-NP+M1 in healthy adult volunteers.
11.
ASSESSMENT OF SAFETY
Safety will be assessed by the frequency, incidence and nature of adverse events and serious adverse events arising during the study.
Definitions Adverse Event (AE)
An AE is any untoward medical occurrence in a volunteer, including a dosing error, which may occur during or after study vaccination and does not necessarily have to have a causal relationship with vaccination. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with study vaccination, whether or not considered related to study vaccination.
Adverse Drug Reaction (ADR)
An ADR is any untoward or unintended response to a medicinal product. This means that a causal relationship between the study medication and an AE is at least a reasonable possibility, i.e., the relationship cannot be ruled out.
Unexpected Adverse Reaction
An unexpected adverse reaction is where the nature or severity is not consistent with the Investigator's Brochure.
Serious Adverse Event (SAE) or Adverse Drug Reaction
An SAE is an AE that results in any of the following outcomes, whether or not considered related to the vaccine.
• Death (i.e., results in death from any cause at any time)
• Life-threatening event (i.e., the volunteer was, in the view of the Investigators, at immediate risk of death from the event that occurred). This does not include an AE that, if it occurred in a more serious form, might have caused death.
• Persistent or significant disability or incapacity (i.e. substantial disruption of one's ability to carry out normal life functions).
• Hospitalisation, regardless of length of stay, even if it is a precautionary measure for continued observation. Hospitalisation (including inpatient or outpatient hospitalization for an elective procedure) for a pre-existing condition that has not worsened unexpectedly does not constitute a serious AE.
• An important medical event (that may not cause death, be life threatening, or require hospitalization) that may, based upon appropriate medical judgment, jeopardize the volunteer and/or require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such medical events include allergic reaction requiring intensive treatment in an emergency room or clinic, blood dyscrasias, or convulsions that do not result in inpatient hospitalization.
• Congenital anomaly or birth defect.
Suspected Unexpected Serious Adverse Reactions (SUSARs)
A SUSAR is different from an SAE in that it is unexpected and thought to be related to the investigational product. Reports of any SUSAR will be sent to the MHRA and GTAC within 7
days for fatal and life-threatening cases and within 15 days for all other SUSARs.
Administration of further vaccines within the trial will be suspended until a safety review is convened.
Expected Adverse Drug Reactions
Expected local reactions to the vaccine will not be recorded as AEs, but will be recorded in the CRFs. These include local redness, swelling, tenderness, or itching.
Expected Serious Adverse Events
No serious adverse events are expected in this study. To date there have been no expected serious adverse events from the current intramuscular or intradermal MVA-NP+M1 vaccine.
Causality Assessment
For every AE, an assessment of the relationship of the event to the administration of the vaccine will be undertaken. An intervention-related AE refers to an AE for which there is a probable or definite relationship to administration of a vaccine. An interpretation of the causal relationship of the intervention to the AE in question will be made, based on the type of event; the relationship of the event to the time of vaccine administration; and the known biology of the vaccine therapy (table 5) . 
Reporting Procedures for All Adverse Events
All AEs occurring up to the week 12 post vaccination visit, observed by the Investigators or reported by the patient, whether or not attributed to study medication, will be reported in the CRF. After the week 12 visit (attendance 7) only data on SAE's and SUSARS will be entered into the CRF. All AEs that result in a patient's withdrawal from the study will be followed up until a satisfactory resolution occurs, or until a non-study related causality is assigned. All deaths occurring during the study will be reported to the Sponsor. For all deaths, available autopsy reports and relevant medical reports will be made available for reporting to the relevant authorities. The severity of events will be assessed according to the scales in table 6. 
Reporting Procedures for Serious Adverse Events
In order to comply with current regulations on serious adverse event reporting to Health Authorities, the event will be documented accurately and notification deadlines respected.
SAEs will be reported to an internal safety group, within 1 working day of the Investigators being aware of their occurrence, as described in internal SOP-TC009. SAEs will not normally be reported to GTAC, unless there is a clinically important increase in occurrence rate, an unexpected outcome, or a new event that is likely to affect safety of trial volunteers.
In addition to the expedited reporting above, the Investigators shall submit once a year throughout the study, or on request, a safety report to the Competent Authority and Ethics Committee.
Procedures to be followed in the event of abnormal findings
Abnormal clinical findings from medical history, examination or blood tests, will be assessed as to their clinical significance. If a test is deemed clinically significant, it may be repeated, to ensure it is not a single occurrence. If a test remains clinically significant, the volunteer will be informed and appropriate medical care arranged as appropriate and with the permission of the volunteer. Decisions to exclude the volunteer from the enrolling in the trial or to withdraw a volunteer from the trial will be at the discretion of the Investigators, following procedures for adverse events as described in section 11.1.
Local Safety Monitor
A Local Safety Monitor (LSM) will be appointed to provide real-time safety oversight. The LSM will review SAEs if deemed possibly, probably or definitely related to vaccination. The LSM will be notified within 1 working day of the Investigators' being aware of their occurrence.
The LSM has the power to terminate the study if deemed necessary following a vaccinerelated SAE.
Safety Profile Review
The safety profile will be assessed on an ongoing basis by the Investigators and specifically after group one has been vaccinated, before enrolling volunteers into group two. An internal safety group will review safety issues and SAEs as they arise. An internal group was deemed appropriate due to extensive experience of this group with this viral vector and the expected adverse events.
12.
STATISTICS This is primarily a safety study. A secondary outcome is to determine substantial differences in the magnitude of immune responses before and after vaccination.
Determination of the Sample Size
This is an observational and descriptive safety study, where 12 subjects will be initially vaccinated intradermally with low dose MVA-NP+M1 followed by 16 subjects intramuscularly. The IM volunteers will be split into 2 equal sized groups, with 8 per group. Group 1 will be vaccinated with 5x10 7 pfu MVANP+M1 and group 2 will be vaccinated with 2.5x10 8 pfu MVANP+M1. A further 30 volunteers over the age of 50 will be vaccinated with 1.5 x 10 8 pfu MVA-NP+_M1, with 10 volunteers in each of 3 aged defined groups (50-59, 60-69 and 70 and above). This sample size should allow determination of the magnitude of the outcome measures, especially of serious and severe adverse events, rather than aiming to obtain statistical significance.
12.1
Statistical Methods
The analysis will be only descriptive, as the sample size does not allow to perform comparison.
QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES
Data will be evaluated for compliance with the protocol and accuracy in relation to source documents. The study will be conducted in accordance with procedures identified in the protocol. SOPs will be used at the clinical and laboratory site. Regular monitoring will be performed according to the requirements of the Medicines for Human Use (Clinical Trial)
Regulations 2004 and ICH Good Clinical Practice (GCP). Following written standard operating procedures, the monitors will verify that the clinical trial is conducted and data are generated, documented and reported in compliance with the protocol, GCP and the applicable regulatory requirements. The Investigator site will provide direct access to all trial related source data/documents and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.
14.
ETHICS
Declaration of Helsinki
The Investigators will ensure that this study is conducted in full conformity with the current 
Informed Consent
Written, informed consent will be obtained, as described in section 7.2.
Independent Ethics Committee (IEC)
A copy of the protocol, proposed informed consent form, other written volunteer information and the proposed advertising material will be submitted to an IEC (GTAC) for written approval. The Investigators will submit and, where necessary, obtain approval from the GTAC for all subsequent substantial amendments to the protocol and informed consent document. The Investigators will notify deviations from the protocol or SAEs occurring at the site to the sponsor and will notify the GTAC of these in accordance with local procedures.
Volunteer Confidentiality
The Investigators will ensure that the volunteer's anonymity is maintained. All documents will be stored securely and kept in strict confidence in compliance with the Data Protection Act.
All computer entry and networking programs will be done with coded numbers and initials only. Only the sponsor representative, Investigators, the clinical monitor, the GTAC and the MHRA will have access to the records. Photographs taken of vaccination sites (with the volunteer's written, informed consent) will not include the volunteer's face and will be identified by the volunteer's 3-digit identification number only. Once developed, photographs will be stored as confidential records, as above. This material may be shown to other professional staff, used for educational purposes, or included in a scientific publication.
15.
DATA HANDLING AND RECORD KEEPING
Data Handling
The Principal Investigator will have overall responsibility for receiving, entering, cleaning, querying, analysing and storing all data that accrues from the study, but these tasks may be delegated to other Investigators. The data will be entered into the volunteers' CRFs. This includes safety data, laboratory data (both clinical and immunological) and outcome data.
Record Keeping
The Investigators will maintain appropriate medical and research records for this trial, in by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress.
Source Data and Case Report Forms (CRFs)
All protocol required information will be collected in CRFs designed by the Investigators. All source documents will be filed in the CRF. Source documents are original documents, data, and records from which the volunteer's CRF data are obtained. For this study, these will include, but are not limited to, volunteer consent form, blood results, GP response letters, laboratory records, diaries, and correspondence. In the majority of cases, CRF entries will be considered source data as the CRF is the site of the original recording (i.e., there is no other written or electronic record of data). In this study this will include, but is not limited to medical history, medication records, vital signs, physical examination records, urine assessments, blood results, adverse event data and details of vaccinations. All source data and volunteer CRFs will be stored securely.
Data Protection
The study protocol, documentation, data and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party, without prior written approval of the sponsor.
FINANCING AND INSURANCE
Financing
The study will be funded by a research grant from the Wellcome Trust held by Dr Sarah Gilbert.
Insurance
Indemnity and/or compensation for harm arising specifically from an accidental injury, and occurring as a consequence of the Research Subject's participation in the Trial for which the University of Oxford is the Research Sponsor will be covered by the University of Oxford.
Compensation
Volunteers will be compensated for their time and for the inconvenience caused by procedures. Volunteers will be compensated £320 (calculated as £12 travel allowance per visit; £8 per hour; £10 per blood donation plus a £30 trial completion bonus).
17.
